Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16202051 | 1.00 | LMNA (0.66) | LMNAPTBP1SMN1; SMN2CYP1A2RAB9A | |
| SCHEMBL12750110 | 0.89 | LMNA (0.48) | LMNAPTBP1SMN1; SMN2CYP1A2MAPT | |
| SCHEMBL6449347 | 0.80 | SMN1; SMN2 (0.47) | LMNAPTBP1SMN1; SMN2CYP1A2RAB9A | |
| SCHEMBL8220014 | 0.80 | LMNA (0.42) | LMNAPTBP1SMN1; SMN2CYP1A2MAPT | |
| SCHEMBL12603677 | 0.80 | CYP1A2 (0.51) | LMNAPTBP1SMN1; SMN2CYP1A2RAB9A | |
| SCHEMBL16322214 | 0.80 | CA12 (0.45) | LMNAPTBP1SMN1; SMN2CYP1A2ALDH1A1 | |
| SCHEMBL16440164 | 0.80 | CYP1A2 (0.51) | LMNAPTBP1SMN1; SMN2CYP1A2RAB9A | |
| SCHEMBL6815200 | 0.80 | CYP1A2 (0.51) | LMNAPTBP1SMN1; SMN2CYP1A2RAB9A | |
| SCHEMBL13514454 | 0.80 | LMNA (0.42) | LMNAPTBP1SMN1; SMN2CYP1A2MAPT | |
| SCHEMBL12757030 | 0.80 | CA12 (0.45) | LMNAPTBP1SMN1; SMN2CYP1A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107739322-B | Synthetic method of sulfonamide compound | 济南大学 | 2020-06-23 | — | — | CN | claimed |
| CN-107739322-B | Synthetic method of sulfonamide compound | 济南大学 | 2020-06-23 | — | — | CN | disclosed |
| CN-101985424-B | Method for synthesizing o-nitroacetophenone compound | UNIV ZHEJIANG TECHNOLOGY | 2013-05-29 | — | — | CN | disclosed |
| CN-101985424-A | Method for synthesizing o-nitroacetophenone compound | UNIV ZHEJIANG TECHNOLOGY | 2011-03-16 | — | — | CN | disclosed |
| US-7109186-B2 | 4-hydroxy-5-oxo-1-(2-[4-methylpiperazin-1-yl]ethyl)-2,5-dihydro-1H-pyrrole-3-carboxylic acid (3,4-dichlorobenzyl)-methyl-amide for human immunodeficiency virus (HIV) treatment | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-19 | — | — | US | disclosed |
| US-6890942-B2 | Acyl sulfonamides as inhibitors of HIV integrase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-05-10 | — | — | US | disclosed |
| US-20050004232-A1 | Acyl sulfonamides as inhibitors of HIV integrase | BRISTOL-MYERS SQUIBB COMPANY | 2005-01-06 | — | — | US | disclosed |
| WO-2004103278-A2 | ACYL SULFONAMIDES AS INHIBITORS OF HIV INTEGRASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-12-02 | — | — | WO | disclosed |
| EP-1467695-A2 | HIV INTEGRASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2004-10-20 | — | — | EP | disclosed |
| US-6777440-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-08-17 | — | — | US | disclosed |
| US-20040110804-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-10 | — | — | US | disclosed |
| WO-2004004657-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-15 | — | — | WO | disclosed |
| US-20030176495-A1 | HIV Integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-18 | — | — | US | disclosed |
| WO-2003049690-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004232-A1 | Acyl sulfonamides as inhibitors of HIV integrase | ACSS2, ARSA, ASS1 | LMNA 4275/4885PTBP1 2768/4885SMN1; SMN2 3245/4885 |
| US-20040110804-A1 | HIV integrase inhibitors | CDKN1A, SAMHD1, CTCF | LMNA 3521/4885PTBP1 1567/4885SMN1; SMN2 4612/4885 |
| US-20030176495-A1 | HIV Integrase inhibitors | MAPT, RIF1, HPRT1 | LMNA 2590/4885PTBP1 2088/4885SMN1; SMN2 3234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.